Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Colorcon
Baxter
Merck
Boehringer Ingelheim

Last Updated: August 19, 2022

Parke Davis Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for PARKE DAVIS, and what generic and branded alternatives to PARKE DAVIS drugs are available?

PARKE DAVIS has one hundred approved drugs.



Summary for Parke Davis
US Patents:0
Tradenames:72
Ingredients:64
NDAs:100

Drugs and US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis NORLESTRIN FE 2.5/50 ethinyl estradiol; ferrous fumarate; norethindrone acetate TABLET;ORAL-28 016854-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Parke Davis NORLESTRIN 28 1/50 ethinyl estradiol; norethindrone acetate TABLET;ORAL-28 016723-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Parke Davis MEPERIDINE HYDROCHLORIDE meperidine hydrochloride INJECTABLE;INJECTION 080364-003 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parke Davis CEREBYX fosphenytoin sodium INJECTABLE;INJECTION 020450-001 Aug 5, 1996 4,925,860 See Plans and Pricing
Parke Davis CHOLYBAR cholestyramine BAR, CHEWABLE;ORAL 071621-001 May 26, 1988 4,778,676 See Plans and Pricing
Parke Davis FEMPATCH estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020417-001 Dec 3, 1996 4,906,463 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PARKE DAVIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
Johnson and Johnson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.